Cellular mechanisms of chronic cell-mediated allergic conjunctivitis

Clinical and Experimental Allergy

Volumn 32, Issue 6, 2002, Pages 814-817

  Calder, V L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; CD4 ANTIGEN; CHROMONE DERIVATIVE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOSPORIN; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; NAKED DNA; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VACCINE;

AGE; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ATOPY; CELL INFILTRATION; CORNEA EROSION; CRYOTHERAPY; DEMOGRAPHY; DISEASE EXACERBATION; DRUG CHOICE; DRUG EFFICACY; EOSINOPHIL; HEREDITY; HUMAN; IMMUNOTHERAPY; LANGERHANS CELL; MAST CELL; PATHOGENESIS; POLLEN; PRIORITY JOURNAL; PROVOCATION; RACE; REVIEW; SEASON; T LYMPHOCYTE; ULTRAVIOLET RADIATION;

EID: 0036283580     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2745.2002.01417.x     Document Type: Review

References (38)

1. Vernal keratoconjunctivitis
2. Clinical features of atopic keratoconjunctivitis
3. Therapeutic options in ocular allergic disease
4. Giant papillary conjunctivitis
5. Giant papillary conjunctivitis in contact lens wearers
6. Vernal keratoconjunctivitis in a Stockholm ophthalmic centre: Epidemiological, functional, and immunologic investigations
7. Vernal keratoconjunctivitis revisited: A case series of 195 patients with long-term follow-up
8. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis
9. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis
10. Ocular allergies: Association with immune dermatitis
11. Atopic keratoconjunctivitis
12. Phenotypic characterization of T cells infiltrating the conjunctiva in chronic allergic eye diseases
13. Accumulation of Th-2-like helper T cells in the conjunctiva of patients with vernal conjunctivitis
14. T cell cytokines in chronic allergic eye disease
15. Production of interleukin-4 and other cytokines following stimulation of mast cell lines and in vivo mast cells/basophils
16. Interleukin-4, -5 and -6 and tumour necrosis factor-alpha in normal and asthmatic airways: Evidence for the human mast cell as a source of these cytokines
17. Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product
18. Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease
19. Identification of local Th2 and ThO lymphocytes in vernal conjunctivitis by cytokine flow cytometry
20. Increased serum levels of eosinophil cationic protein and eosinophil-derived neurotoxin (protein X) in vernal keratoconjunctivitis
21. Eosinophilic cationic protein in tears in allergic conjunctivitis
22. The role of eosinophilic cationic protein and histamine in vernal keratoconjunctivitis
23. Eosinophils, allergy and parasites
24. Eosinophil granule proteins and their role in disease
25. Human eosinophils express a receptor for secretory component. Role in secretory IgA-dependent activation
26. Updates on cells and cytokines: Human eosinophils
27. Synthesis of type 1 (IFN gamma) and type 2 (IL-4, IL-5, and IL-10) cytokines by human eosinophils
28. Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): Inhibition by immunoglobulin a complexes
29. Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints
30. TNF alpha is an effective therapeutic target for rheumatoid arthritis
31. Safety, efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis
32. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Infliximab and methotrexate in the treatment of rheumatoid arthritis
33. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
34. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial
35. New treatment options in spondylo-arthropathies: Increasing evidence for significant efficacy of anti-tumor necrosis factor therapy
36. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses
37. Clinical efficacy of specific immunotherapy to cat dander: A double-blind placebo-controlled trial
38. Treatment of cat allergy with T-cell reactive peptides